Table 2 LT4 formulations preferred by respondents in different clinical scenarios
| Â | Tablets, n (%) | Soft-gel capsules, n (%) | Liquid Solutions, n (%) | I expect no major changes with different formulations, n (%) |
|---|---|---|---|---|
Interfering drugs may influence the stability of therapy. Which LT4 preparation is, in your experience, less likely to be subject to variable absorption? | 33 (40.7) | 20 (24.7) | 19 (23.5) | 9 (11.1) |
Which of the following preparations of LT4 would you prescribe in case of a first diagnosis of hypothyroidism, when the patient self-reports intolerance to various foods, raising the possibility of celiac disease, malabsorption, lactose intolerance or intolerance to excipients? | 37 (45.7) | 16 (19.8) | 20 (24.7) | 8 (9.9) |
Which of the following preparations of LT4 would you prescribe for a patient established on generic LT4 who has unexplained poor biochemical control of hypothyroidism? | 32 (39.5) | 18 (22.2) | 17 (21) | 14 (17.3) |
Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasting and separate from food/drink? | 35 (43.2) | 16 (19.8) | 20 (24.7) | 10 (12.3) |
Which of the following preparations of LT4 would you prescribe for a patient established on generic T4 who has good biochemical control of hypothyroidism, but continue to have symptoms? | 41 (50.6) | 4 (4.9) | 9 (11.1) | 27 (33.3) |